Evidence map›Paper›PMID 33506199›Full record

ArticleNeuro-oncology advances

An integrated disease-specific graded prognostic assessment scale for melanoma: contributions of KPS, CITV, number of metastases, and BRAF mutation status.

Manmeet Ahluwalia, Mir A Ali, Rushikesh S Joshi, Eun Suk Park, Birra Taha, Ian McCutcheon, Veronica Chiang, Angela Hong, Georges Sinclair, Jiri Bartek and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 4 countries.

Manmeet AhluwaliaBrain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio, USA.
Mir A AliDepartment of Neurosurgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Rushikesh S JoshiSchool of Medicine, University of California San Diego, San Diego, California, USA.ORCID 0000-0001-5251-5856
Eun Suk ParkDepartment of Neurosurgery, University of Minnesota, Minneapolis, Minnesota, USA.
Birra TahaDepartment of Neurosurgery, University of Minnesota, Minneapolis, Minnesota, USA.
Ian McCutcheonDepartment of Neurosurgery, MD Anderson Cancer Center, Houston, Texas, USA.
Veronica ChiangDepartment of Neurosurgery, Yale University School of Medicine, and Yale Cancer Center, New Haven, Connecticut, USA.
Angela HongMelanoma Institute Australia, Wollstonecraft, NSW, Australia.
Georges SinclairDepartment of Oncology, James Cook University Hospital, Middlesbrough, UK.
Jiri BartekDepartment of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden.
Clark C ChenDepartment of Neurosurgery, University of Minnesota, Minneapolis, Minnesota, USA.
University of Minnesota · USKarolinska University Hospital · SECleveland Clinic · USMelanoma Institute Australia · AUThe University of Texas MD Anderson Cancer Center · USUniversity of California San Diego · USVanderbilt University Medical Center · USYale Cancer Center · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

backgroundStereotactic radiosurgery (SRS) remains a mainstay therapy in the treatment of melanoma brain metastases (BM). While prognostic scales have been developed for melanoma patients who underwent SRS treatment for BM, the pertinence of these scales in the context of molecularly targeted therapies remains unclear.

methodsThrough a multi-institutional collaboration, we collated the survival patterns of 331 melanoma BM patients with known BRAF mutation status treated with SRS. We established a prognostic scale that was validated in an independent cohort of 174 patients. All patients with BRAF mutations in this series were treated with BRAF inhibitors. Prognostic utility was assessed using Net Reclassification Index (NRI > 0) and integrated discrimination improvement (IDI) metrics.

resultsIn a multivariate Cox proportional hazards model, BRAF mutation status, KPS, number of metastases, and cumulative intracranial tumor volume (CITV) independently contributed to survival prognostication for melanoma patients with SRS-treated BM (

conclusionsOptimal survival prognostication for SRS-treated patients with melanoma BM requires an integrated assessment of patient characteristics (KPS), tumor characteristics (CITV and number of metastases), and the mutational profile of the melanoma (BRAF mutation status).

Indexed as

BRAFbrain metastasisCITVds-GPAmelanoma

Identifiers

PMID33506199
PMCPMC7810198
OpenAlexW3102730520

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.